{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"alpelisib\" outputclass=\"int-drug\">alpelisib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor for toxicity</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   alpelisib .  Manufacturer advises caution and monitor for toxicity .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alpelisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"antacids\" outputclass=\"int-drug\">antacids</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   antacids   decrease   the absorption of   oral   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Antacids</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"atorvastatin\" outputclass=\"int-drug\">atorvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   atorvastatin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atorvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"berotralstat\" outputclass=\"int-drug\">berotralstat</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   berotralstat .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Berotralstat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium acetate\" outputclass=\"int-drug\">calcium acetate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"calcium acetate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-acetate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP104228\">calcium acetate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium acetate   decreases   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  calcium acetate .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium acetate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"calcium carbonate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93602\">calcium carbonate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  calcium carbonate .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium carbonate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium chloride\" outputclass=\"int-drug\">calcium chloride</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"calcium chloride\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-chloride.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93603\">calcium chloride</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium chloride   decreases   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  calcium chloride .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium gluconate\" outputclass=\"int-drug\">calcium gluconate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"calcium gluconate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-gluconate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93600\">calcium gluconate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium gluconate   decreases   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  calcium gluconate .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium gluconate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium lactate\" outputclass=\"int-drug\">calcium lactate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"calcium lactate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-lactate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93601\">calcium lactate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium lactate   decreases   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  calcium lactate .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium lactate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"calcium phosphate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  calcium phosphate .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium phosphate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">Ciclosporin</ph> <ph outputclass=\"int-effect\">causes a small decrease in</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor platelet count and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ciclosporin   causes a small decrease in   the exposure to   eltrombopag .  Manufacturer advises monitor platelet count and adjust dose .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fluvastatin\" outputclass=\"int-drug\">fluvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   fluvastatin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   eltrombopag .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"iron\" outputclass=\"int-drug\">iron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after iron</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   iron   is predicted to   decrease   the absorption of   oral   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after iron .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"larotrectinib\" outputclass=\"int-drug\">larotrectinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   larotrectinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Larotrectinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"letermovir\" outputclass=\"int-drug\">letermovir</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the concentration of   letermovir .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Letermovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the concentration of   methotrexate .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to the active metabolites of</ph> <ph otherprops=\"ozanimod\" outputclass=\"int-drug\">ozanimod</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to the active metabolites of   ozanimod .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ozanimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pravastatin\" outputclass=\"int-drug\">pravastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   pravastatin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pravastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph> and <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">rifampicin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   eltrombopag  and  eltrombopag   is predicted to   increase   the concentration of   rifampicin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   rosuvastatin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rosuvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"selenium\" outputclass=\"int-drug\">selenium</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"selenium\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/selenium.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP6176\">selenium</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   selenium   is predicted to   decrease   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  selenium .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selenium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"simvastatin\" outputclass=\"int-drug\">simvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   simvastatin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Simvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"talazoparib\" outputclass=\"int-drug\">talazoparib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   talazoparib .  Manufacturer advises avoid or monitor .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Talazoparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   tenofovir alafenamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenofovir alafenamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir disoproxil\" outputclass=\"int-drug\">tenofovir disoproxil</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   tenofovir disoproxil .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenofovir disoproxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">Eltrombopag</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venetoclax\" outputclass=\"int-drug\">venetoclax</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor for toxicity</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eltrombopag   is predicted to   increase   the exposure to   venetoclax .  Manufacturer advises avoid or monitor for toxicity .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venetoclax</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2#bnf_i1643857958489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"zinc\" outputclass=\"int-drug\">zinc</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"zinc\" outputclass=\"int-drug\">zinc</ph> (<ph otherprops=\"zinc acetate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/zinc-acetate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP6306\">zinc acetate</xref></ph>, <ph otherprops=\"zinc sulfate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/zinc-sulfate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP6172\">zinc sulfate</xref></ph>)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   zinc   is predicted to   decrease   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  zinc  ( zinc acetate ,  zinc sulfate ) .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zinc</title>"
					}
				}
			],
			"hasSearchLabel": " Eltrombopag  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/eltrombopag-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Eltrombopag </title>"
			},
			"rdfs:label": "eltrombopag"
		}
	]
}